Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease
Autore:
Arslan, M; Wiesner, RH; Sievers, C; Egan, K; Zein, NN;
Indirizzi:
Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol & Internal Med, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn Rochester MN USA 55905 Med, Rochester, MN 55905 USA Mayo Clin, Biostat Sect, Rochester, MN USA Mayo Clin Rochester MN USAMayo Clin, Biostat Sect, Rochester, MN USA
Titolo Testata:
LIVER TRANSPLANTATION
fascicolo: 4, volume: 7, anno: 2001,
pagine: 314 - 320
SICI:
1527-6465(200104)7:4<314:DAHBVI>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRANSPLANT RECIPIENTS; HEMODIALYSIS-PATIENTS; ANTIBODY-RESPONSE; VIRUS-INFECTION; IMMUNOGENICITY; TRANSMISSION; IMMUNIZATION; CANDIDATES; EFFICACY; FAILURE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Zein, NN Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol & Internal Med,200 1st St SW, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn 200 1st St SW Rochester MN USA 55905 905 USA
Citazione:
M. Arslan et al., "Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease", LIVER TRANS, 7(4), 2001, pp. 314-320

Abstract

The aims of this study are to assess the efficacy of hepatitis B virus (HBV) vaccination using an accelerated schedule and double dose of recombinantvaccine in liver transplant recipients and identify factors associated with seroconversion and persistence of antibody to hepatitis B surface antigen(anti-HBs). Three hundred fifty-six patients were enrolled. Exclusion criteria were previous HBV infection, fulminant liver failure, or less than 2 years of follow-up after orthotopic liver transplantation (OLT). The vaccination schedule was 0, 2 weeks, 4 weeks, and 6 months using double-dose recombinant vaccine. Seroconversion was evaluated prospectively by measuring anti-HBs on the day of OLT and 1 and 2 years after OLT. Quantitative analyses of anti-HBs were performed retrospectively on stored sera Geometric mean concentrations (GMCs) were calculated using a standard formula. All patients completed the full vaccination schedule, and 129 patients (36%) completed the schedule before OLT. The overall prevalence of anti-HBs was 128 of 356 pre-OLT samples (36%) compared with 41 of 353 (11.6%) and 26 of 325 post-OLTsamples (8%) 1 and 2 years after OLT, respectively (both P = .001). The pre-OLT GMC was 86.7 compared with 0.32 and 0.33 at 1 and 2 years after OLT, respectively (P = .001). Patients with high titers of anti-HBs before OLT were more likely to have persistence of antibodies 1 or 2 years after OLT. Younger age (P = .02), low Child-Pugh score (P =.02), underlying chronic hepatitis C (P = .03), and specific host HLA subtypes were most strongly associated with seroconversion and/or persistence of anti-HBs. Thus, (I) seroconversion before or after OLT using double-dose accelerated-schedule vaccination against HBV is low, (2) there is a rapid, significant decrease in antibody titer after OLT, (3) pre-OLT anti-HBs titer potentially may be useful in predicting persistence of protective antibodies after OLT, and (4) several factors (age, genetic predisposition, severity of liver disease, and underlying liver disease) may have a role in poor vaccine responsiveness.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 09:25:24